NEW YORK, Sept. 23, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany. These investigator-initiated studies are being conducted as part of…


Previous articleATMA Journey Centers Offer Regulated Health Care Professionals a Means to Incorporate Psychedelic-Assisted Psychotherapy Into Their Practice
Next articleAwakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London